



Year: 2006

Effect of concurrent vitamin A and iodine deficiencies on the thyroid-pituitary axis in rats

Biebinger, R; Arnold, M; Koss, M; Kloeckener-Gruissem, B; Langhans, W; Hurrell, R F; Zimmermann, M B

Abstract: **OBJECTIVE:** Deficiencies of vitamin A and iodine are common in many developing countries. Vitamin A deficiency (VAD) may adversely affect thyroid metabolism. The study aim was to investigate the effects of concurrent vitamin A and iodine deficiencies on the thyroid-pituitary axis in rats. **DESIGN:** Weanling rats (n = 56) were fed diets deficient in vitamin A (VAD group), iodine (ID group), vitamin A and iodine (VAD + ID group), or sufficient in both vitamin A and iodine (control) for 30 days in a paired design. Serum retinol (SR), thyroid hormones (FT(4), TT(4), FT(3), and TT(3)), serum thyrotropin (TSH), pituitary TSHbeta mRNA expression levels, and thyroid weights were determined at the end of the depletion period. **MAIN OUTCOME:** Compared to the control and ID groups, SR concentrations were about 35% lower in the VAD and VAD + ID groups ($p < 0.001$), indicating moderate VA deficiency. Comparing the VAD and control groups, there were no significant differences in TSH, TSHbeta mRNA, thyroid weight, or thyroid hormone levels. Compared to the control group, serum TSH, TSHbeta mRNA, and thyroid weight were higher ($p < 0.05$), and FT4 and TT4 were lower ($p < 0.001$), in the VAD + ID and ID groups. Compared to the ID group, TSH, TSHbeta mRNA, and thyroid weight were higher ($p < 0.01$) and FT(4) and TT(4) were lower ($p < 0.001$) in the VAD + ID group. There were no significant differences in TT3 or FT3 concentrations among groups. **CONCLUSION:** Moderate VAD alone has no measurable effect on the pituitary-thyroid axis. Concurrent ID and VAD produce more severe primary hypothyroidism than ID alone.

DOI: <https://doi.org/10.1089/thy.2006.16.961>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-38709>

Journal Article

Originally published at:

Biebinger, R; Arnold, M; Koss, M; Kloeckener-Gruissem, B; Langhans, W; Hurrell, R F; Zimmermann, M B (2006). Effect of concurrent vitamin A and iodine deficiencies on the thyroid-pituitary axis in rats. *Thyroid*, 16(10):961-965.

DOI: <https://doi.org/10.1089/thy.2006.16.961>

Effect of Concurrent Vitamin A and Iodine Deficiencies on the Thyroid-Pituitary Axis in Rats

Ralf Biebinger,¹ Myrtha Arnold,² Michael Koss,² Barbara Kloeckener-Gruissem,³ Wolfgang Langhans,² Richard F. Hurrell,¹ and Michael B. Zimmermann¹

Objective: Deficiencies of vitamin A and iodine are common in many developing countries. Vitamin A deficiency (VAD) may adversely affect thyroid metabolism. The study aim was to investigate the effects of concurrent vitamin A and iodine deficiencies on the thyroid-pituitary axis in rats. **Design:** Weanling rats ($n = 56$) were fed diets deficient in vitamin A (VAD group), iodine (ID group), vitamin A and iodine (VAD + ID group), or sufficient in both vitamin A and iodine (control) for 30 days in a pair-fed design. Serum retinol (SR), thyroid hormones (FT_4 , TT_4 , FT_3 , and TT_3), serum thyrotropin (TSH), pituitary $TSH\beta$ mRNA expression levels, and thyroid weights were determined at the end of the depletion period. **Main outcome:** Compared to the control and ID groups, SR concentrations were about 35% lower in the VAD and VAD + ID groups ($p < 0.001$), indicating moderate VA deficiency. Comparing the VAD and control groups, there were no significant differences in TSH, $TSH\beta$ mRNA, thyroid weight, or thyroid hormone levels. Compared to the control group, serum TSH, $TSH\beta$ mRNA, and thyroid weight were higher ($p < 0.05$), and FT_4 and TT_4 were lower ($p < 0.001$), in the VAD + ID and ID groups. Compared to the ID group, TSH, $TSH\beta$ mRNA, and thyroid weight were higher ($p < 0.01$) and FT_4 and TT_4 were lower ($p < 0.001$) in the VAD + ID group. There were no significant differences in TT_3 or FT_3 concentrations among groups. **Conclusion:** Moderate VAD alone has no measurable effect on the pituitary-thyroid axis. Concurrent ID and VAD produce more severe primary hypothyroidism than ID alone.

Introduction

VITAMIN A DEFICIENCY (VAD) and iodine deficiency (ID) are major global public health problems, affecting more than 30% of the population worldwide (1). In many regions of the developing world, vulnerable groups, such as young women, infants, and children, suffer from both VAD and ID (2,3). In areas of endemic goiter, micronutrient status is an important determinant of iodine and thyroid metabolism (4). Deficiencies of selenium (5) and iron (2) can act in concert with iodine deficiency to impair thyroid metabolism and modify the response to prophylactic iodine (6,7).

In animals, VAD has multiple effects on thyroid metabolism. Severe VAD decreases thyroidal iodine uptake, impairs thyroglobulin (Tg) synthesis, and increases thyroid size (8,9). In the periphery, VAD increases free and total circulating thyroid hormone (10–13), and binding of transthyretin (TTR) to retinol-binding protein (RBP) decreases VA turnover and enhances VA delivery (14,15). Centrally, because retinoic acid suppresses transcription of the pituitary $TSH\beta$ gene through activation of the retinoid X receptor (RXR) (16–18),

VA status may modulate thyroxine (T_4) feedback of thyrotropin (TSH) secretion. VAD in rats increases pituitary $TSH\beta$ mRNA and TSH secretion; both return to normal after treatment with retinoic acid (19).

In a recent study in African children with ID and VAD, increasing VAD severity was a predictor of greater thyroid volume and higher concentrations of TSH and T_4 (3). This study suggested that VAD in goitrous children increases TSH stimulation and thyroid size, and reduces risk for hypothyroidism, an effect that could be due to modulation of the pituitary $TSH\beta$ gene by VA (3). Therefore, the aim of this study was to investigate the effects of concurrent VAD and ID on the thyroid-pituitary axis in rats.

Materials and Methods

Animals and diets

The Veterinary Office of the Canton of Zurich's Department of Health gave the ethical approval for the study. Male weanling Sprague-Dawley rats ($n = 56$; Charles River

¹Human Nutrition Laboratory, Institute of Food Science and Nutrition, ETH Zurich, Switzerland.

²Physiological and Animal Husbandry, Institute of Animal Sciences, ETH Zurich, Switzerland.

³Division of Medical Molecular Genetics and Gene Diagnostics, Institute of Medical Genetics, University of Zurich, Switzerland.

GmbH, Germany) at 21 ± 3 days of age were housed individually in random order in stainless steel cages with grated stainless steel floors. The rats were kept under controlled conditions at 21°C and 55% humidity with a 12-hour light:dark cycle. Rats consumed Millipore water (Milli-Q UF Plus, Millipore, Bedford, MA) *ad libitum*. The diets were prepared by Dyets Inc. (Bethlehem, PA) following the AIN-93G purified rodents guidelines (20), and were based on L-amino acids to avoid iodine contamination from casein as a major protein source.

Study design

The depletion period lasted 30 days. The rats ($n = 8$ in each group) were randomly divided into seven groups: a control group fed a VA- and iodine-sufficient diet (control group), a group fed the VA-deficient diet (VAD group), a group fed the iodine-deficient diet (ID group), and a group fed the VA and iodine-deficient diet (VAD + ID group). Animals in the VAD, ID, and VAD + ID groups were matched to pair-fed animals fed the control diet ($n = 8$ in each of the three pair-fed groups). All animals were handled daily to reduce stress at blood collection and sacrifice. Food intake was recorded daily and the body weight was measured three times per week. Blood was collected by tail vein incision (21) and serum was stored at -20°C . After the animals were killed by decapitation, the thyroid and pituitary were immediately dissected and removed. Thyroid dissection was done using a dissecting microscope under supervision of an experienced animal technician. Thyroids were weighed immediately after dissection, and then wrapped in aluminum foil, shock frozen in liquid nitrogen, and stored at -60°C . The pituitaries were dissected within 60 seconds and stored in RNAlater solution (RNeasy Protect Mini Kit, cat. no. 74104, Qiagen GmbH Hilden, Germany) at -60°C .

Laboratory analysis

Free and total thyroxine and triiodothyronine (FT_4 , TT_4 , FT_3 , and TT_3) and serum TSH were measured using immunoluminescent assays (IMMULITE[®], Buehmann Laboratories AG, Switzerland). Serum retinol (SR) was measured with an optimized high-pressure liquid chromatography method (22,23). For measurement of $\text{TSH}\beta$ mRNA, total RNA extraction was done using the RNeasy Protect Mini Kit (Qiagen GmbH, Hilden, Germany), with samples stored after each working step at -80°C . To avoid DNA contamination, a DNA on column digestion was carried out during the total RNA extraction (RNase-free DNase set, cat. no. 79252, Qiagen GmbH Hilden, Germany). $\text{TSH}\beta$ mRNA expression levels were measured with SYBR-Green[®] one-step RT-qPCR (QuantiTect SYBR Green RT-PCR Kit, cat. no. 204243, Qiagen GmbH, Hilden, Germany) using an ABI Prism 7900 Thermocycler (Applied Biosystems, Foster City, CA). The specific primer pairs were purchased from Qiagen, Germany. $\text{TSH}\beta$ mRNA expression levels were normalized with a housekeeping gene (*Hprt*). For each animal, five replicates for the target gene and three replicates for the housekeeping gene were performed.

Statistical analysis

Data processing and analysis were done using SPSS 13.0 (SPSS Chicago, IL) and Microsoft Excel 2002 (Seattle, WA).

Data not normally distributed (TSH) were log transformed before comparisons. Comparisons between the treatment groups were done with analysis of variance. If the interaction effect was significant, *t* tests were done and adjusted for multiple comparisons (Bonferroni). Significance was set at $p < 0.05$.

Results

Compared to the control group, there was no significant difference in any of the measured biochemical or anatomic variables in the pair-fed groups (data not shown). Food intake and body weights (grams) did not differ significantly in all treatment groups; body weights were as follows: control 267 ± 16 , VAD 258 ± 17 , ID 260 ± 14 , VAD + ID 281 ± 25 . As shown in Table 1, compared to the ID and control groups, SR concentrations were about 35% lower in the VAD and VAD + ID groups ($p < 0.001$), indicating moderate VA deficiency. There was no significant difference in SR comparing the VAD + ID and VAD groups.

Serum concentrations of TSH, TT_3 , FT_3 , TT_4 , and FT_4 , and thyroid weights among the groups are shown in Table 1. Levels of pituitary $\text{TSH}\beta$ mRNA among the groups are shown in Figure 1. Comparing VAD to control, there was no significant difference in TT_3 , FT_3 , TT_4 , or FT_4 . In ID and ID + VAD groups, FT_4 and TT_4 were lower compared to the control group ($p < 0.001$). FT_4 and TT_4 were lower in the ID + VAD group compared to the ID group ($p < 0.05$). There were no significant differences in TT_3 or FT_3 concentrations between the groups. Mean TSH, $\text{TSH}\beta$ mRNA, and thyroid weight were significantly greater in the VAD + ID and ID groups compared to the control group ($p < 0.05$). TSH, $\text{TSH}\beta$ mRNA, and thyroid weight were significantly greater in the VAD + ID group compared to the ID group ($p < 0.01$).

Discussion

Our findings demonstrate that combined deficiencies of VA and iodine have greater adverse effects on the pituitary–thyroid axis compared to single deficiencies of VA or iodine. The data from the pair-fed controls indicate that these changes were not due to reduced food intake. Compared to the ID group, TSH, $\text{TSH}\beta$ mRNA, and thyroid weight were $\approx 30\%$ higher in the VAD + ID group. Compared to the ID group, FT_4 and TT_4 were reduced by $>50\%$ and $>75\%$, respectively, in the VAD + ID group. Thus, concurrent VAD aggravates ID-induced primary hypothyroidism.

There are several potential mechanisms that could explain this effect. In iodine-sufficient animals, severe VAD alone causes thyroid hypertrophy (9,24), reduces thyroidal iodine uptake (25), impairs synthesis of Tg and coupling of iodotyrosine residues to form thyroid hormone (8), and decreases intrathyroidal T_3 and T_4 (8,9). In the periphery, severe VAD increases total and free T_3 and T_4 (8,10), reduces hepatic conversion of T_4 to T_3 (8,26), and decreases T_3 uptake and binding (11,12). Because we did not measure deiodinase expression and/or activity in the thyroid or the liver, this study does not provide data on these potential mechanisms.

Although we did not measure thyroid binding proteins or binding affinity in this study, VAD may affect thyroid metabolism through shared transport proteins. In humans, thyroid-binding globulin (TBG) carries the majority of T_4 and T_3 in plasma (ca. 70%), whereas TTR binds 10–15% (14). Rats lack TBG and show different binding ratios between thyroid

TABLE 1. MEAN VALUES \pm SD FOR SERUM RETINOL, TSH, THYROID WEIGHT, AND THYROID HORMONE CONCENTRATIONS IN WEANLING RATS FED DIETS DEFICIENT IN VITAMIN A (VAD GROUP), IODINE (ID GROUP), VITAMIN A AND IODINE (VAD + ID GROUP), OR SUFFICIENT IN BOTH VITAMIN A AND IODINE (CONTROL) FOR 30 DAYS

	Control	VAD	ID	VAD + ID
Serum retinol ($\mu\text{g}/\text{dL}$)	52.71 \pm 5.93	33.93 \pm 3.61 ^a	51.70 \pm 4.73	31.61 \pm 2.33 ^a
TSH (mIU/mL)*	0.13 \pm 0.35	0.14 \pm 0.11	0.29 \pm 0.11 ^{b,d}	0.77 \pm 0.30 ^{b,d}
Thyroid weight (mg)	17.5 \pm 2.2	14.2 \pm 3.1	26.4 \pm 5.9 ^{b,d}	37.8 \pm 9.4 ^{b,d}
TT ₄ ($\mu\text{g}/\text{dL}$)	6.56 \pm 0.65	6.60 \pm 0.62	3.98 \pm 1.37 ^{c,d}	1.16 \pm 0.31 ^{c,d}
FT ₄ (ng/dL)	3.27 \pm 0.46	3.35 \pm 0.36	2.06 \pm 0.60 ^{c,d}	0.95 \pm 0.44 ^{c,d}
TT ₃ (ng/dL)	135.36 \pm 18.49	135.71 \pm 20.69	124.36 \pm 22.42	107.47 \pm 16.93
FT ₃ (pg/mL)	5.64 \pm 0.67	5.80 \pm 1.59	4.60 \pm 1.12	5.10 \pm 0.86

*Data were log transformed for statistical analysis.

^aSignificantly different from control and ID group ($p < 0.001$; ANOVA, *post-hoc* test: Bonferroni).

^{b,c}Significantly different from control and VAD group (^b $p < 0.05$, ^c $p < 0.01$; ANOVA, *post-hoc* test: Bonferroni).

^dSignificantly different between ID and VAD + ID group ($p < 0.01$; ANOVA, *post-hoc* test: Bonferroni).

transport proteins (27). In rats and humans, TTR is a primary indirect carrier of VA; RBP is secreted from the hepatocyte as a complex with TTR, and binding of RBP to TTR prevents renal clearance of RBP, thereby enhancing VA delivery (28,29). Although VAD decreases hepatic release of RBP, release of TTR and serum TTR concentrations are similar during vitamin A depletion and repletion in rats (30,31). However, animal studies have suggested binding capacity and affinity of TTR for thyroid hormone may be modified by interaction with RBP (28,32–34).

VAD may also affect thyroid metabolism through a central mechanism. Both the thyroid hormone-activated thyroid receptor and the retinoic acid-activated retinoid X receptor suppress transcription of the pituitary TSH β gene by occupying half-sites on the promoter DNA of the gene (16–18). Breen et al. (19) found that severe VAD in rats increased pituitary TSH β mRNA levels twofold, and increased serum TT₄; both returned to normal after VA treatment. They con-

cluded that the increased TSH β mRNA despite high serum TT₄ implied VAD had made the pituitary thyrotrope relatively insensitive to feedback control by thyroid hormone. In pair-fed rats with VAD, Morley et al. (10) also found an increase in hypothalamic thyrotropin-releasing hormone and pituitary TSH despite high circulating thyroid hormone. In contrast to these previous studies in severely VA-deficient rats, where higher TSH concentrations in the face of higher circulating TT₄ suggest central resistance to normal TSH suppression by thyroid hormone, our data suggest that moderate VAD alone does not adversely affect the pituitary-thyroid axis.

To our knowledge, this is the first study to demonstrate that VAD in the presence of ID enhances the overexpression of TSH β that is characteristic of ID. Mean TSH β mRNA was more than 100% higher in the VAD + ID group compared to the ID group. Increased expression of TSH β was likely due to aggravation of primary hypothyroidism; that is, lower




FIG. 1. Pituitary thyrotropin β mRNA concentrations in weanling rats fed diets deficient in vitamin A (VAD group), iodine (ID group), vitamin A and iodine (VAD + ID group), or sufficient in both vitamin A and iodine (control) for 30 days. a: Significantly different from control group ($p < 0.05$; ANOVA, *post-hoc* test: Bonferroni). b: Significantly different between ID and VAD + ID group ($p < 0.01$; ANOVA, *post-hoc* test: Bonferroni).

circulating T₄ levels in the VAD + ID group compared to the ID group stimulated greater TSH β mRNA production. It is also possible that VAD, in the setting of ID, enhanced TSH β mRNA expression through reduced suppression by the thyroid hormone-activated thyroid receptor and the retinoic acid (RA)-activated retinoid X receptor of the pituitary TSH β gene. Haugen et al. (18), in an *in vitro* study, reported that both T₃ and RA independently suppress promoter activity. Li et al. (35,36) have suggested that the retinoid X receptor (RXR) component in a thyroid hormone receptor TR/RXR heterodimer is not a silent partner, but has important regulatory effects on the expression of the pituitary TSH β gene.

One previous study examined the effect of concurrent VAD + ID in rats. Ingenbleek (8) provided rats either iodine-deficient (ID), vitamin A-deficient (VAD), or iodine and vitamin A-deficient (ID + VAD) diets for 60 days. Concentrations of FT₄ and TT₄ were greater in the VAD group, lower in the ID group, and intermediate in the VAD + ID group, compared to control. Serum TSH and TT₃ concentrations were increased in both the ID and the VAD + ID group. In the VAD and VAD + ID groups, synthesis of Tg and coupling of iodotyrosine residues to form thyroid hormone was impaired, and it was suggested that this was the primary cause of the adverse effects of VAD on thyroid metabolism (8). These data differ from our findings; in our study, VAD alone had no effect on thyroid metabolism, and there was no change in T₃ levels and a significant decrease in T₄ in the VAD + ID group. Differences in study design likely explain the varying findings between the two studies. The depletion period was twice as long in the study by Ingenbleek, and serum retinol levels fell to 10% of the control group, indicating severe VAD. Also, the rats were not pair-fed in that study (8), and significant decreases in body weight in the VAD and VAD + ID groups may have confounded the results.

The results of the present study differ somewhat from the findings of our previous study in African children with ID and VAD, where increasing VAD severity was a predictor of greater thyroid volume and higher concentrations of TSH and T₄ (3). Both studies found an increase in TSH concentration and thyroid size in concurrent ID and VAD, but in the present study, thyroid hormone concentrations were decreased. This difference could be due to several factors, including differences in study design, varying degrees of VAD, and/or confounding factors in the human, cross-sectional study, such as other nutritional deficiencies in the children.

Acknowledgments

This study was supported by the Swiss National Science Foundation (Bern, Switzerland). We thank Isabelle Aeberli, Frank Bootz, Doreen Häberer, Noemi Hernadalvfi, and Fabian Rohner (Zurich, Switzerland) for their assistance during the study. None of the authors had a financial or personal conflict of interest with regard to this study.

References

1. WHO 2004 Iodine status worldwide: WHO global database on iodine deficiency. de Benoist B, Andersson M, Egli I, Takkouche B, Allen B (eds.). WHO Geneva.
2. Zimmermann M, Adou P, Torresani T, Zeder C, Hurrell R 2000 Persistence of goiter despite oral iodine supplementation in goitrous children with iron deficiency anemia in Cote d'Ivoire. *Am J Clin Nutr* **71**:88–93.
3. Zimmermann MB, Wegmuller R, Zeder C, Chaouki N, Torresani T 2004 The effects of vitamin A deficiency and vitamin A supplementation on thyroid function in goitrous children. *J Clin Endocrinol Metab* **89**:5441–5447.
4. Zimmermann MB, Kohrle J 2002 The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. *Thyroid* **12**:867–878.
5. Vanderpas JB, Contempré B, Duale NL, Deckx H, Bebe N, Longombe AO, Thilly CH, Diplock AT, Dumont JE 1993 Selenium deficiency mitigates hypothyroxinemia in iodine-deficient subjects. *Am J Clin Nutr* **57**:271S–275S.
6. Hess SY, Zimmermann MB, Adou P, Torresani T, Hurrell RF 2002 Treatment of iron deficiency in goitrous children improves the efficacy of iodized salt in Cote d'Ivoire. *Am J Clin Nutr* **75**:743–748.
7. Zimmermann MB, Zeder C, Chaouki N, Torresani T, Saad A, Hurrell RF 2002 Addition of microencapsulated iron to iodized salt improves the efficacy of iodine in goitrous, iron-deficient children: a randomized, double-blind, controlled trial. *Eur J Endocrinol* **147**:747–753.
8. Ingenbleek Y 1983 Vitamin A deficiency impairs the normal mannosylation, conformation and iodination of the thyroglobulin: a new etiological approach to endemic goiter. *Experientia Suppl* **44**:264–297.
9. Oba K, Kimura S 1980 Effects of vitamin A deficiency on thyroid function and serum thyroxine levels in the rat. *J Nutr Sci Vitaminol (Tokyo)* **26**:327–334.
10. Morley JE, Damassa DA, Gordon J, Pekary AE, Hershman JM 1978 Thyroid function and vitamin A deficiency. *Life Sci* **22**:1901–1905.
11. Higuieret P, Garcin H 1984 Triiodothyronine and vitamin A deficiency in the rat. *J Physiol (Paris)* **79**:373–377.
12. Higuieret P, Paillet I, Garcin H 1989 Vitamin A deficiency and tri-iodothyronine action at the cellular level in the rat. *J Endocrinol* **121**:75–79.
13. Morley JE, Melmed S, Reed A, Kasson BG, Levin SR, Pekary AE, Hershman JM 1980 Effect of vitamin A on the hypothalamo-pituitary-thyroid axis. *Am J Physiol* **238**:E174–E179.
14. Robbins J 2000 Thyroid hormone transport proteins and the physiology of hormone binding. In: Braverman LE, Utiger RD (eds) *The Thyroid: A Fundamental and Clinical Text*. 8th ed. Lippincott, Philadelphia, pp 105–120.
15. Raz A, Goodman DS 1969 The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. *J Biol Chem* **244**:3230–3237.
16. Wolf G 2002 The regulation of the thyroid-stimulating hormone of the anterior pituitary gland by thyroid hormone and by 9-cis-retinoic acid. *Nutr Rev* **60**:374–377.
17. Bhutta ZA, Bird SM, Black RE, Brown KH, Gardner JM, Hidayat A, Khatun F, Martorell R, Ninh NX, Penny ME, Rosado JL, Roy SK, Ruel M, Sazawal S, Shankar A 2000 Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. *Am J Clin Nutr* **72**:1516–1522.
18. Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC 1997 The thyrotrope-restricted isoform of the retinoid-X receptor-gamma1 mediates 9-cis-retinoic acid suppression of thyrotropin-beta promoter activity. *Mol Endocrinol* **11**:481–489.
19. Breen JJ, Matsuura T, Ross AC, Gurr JA 1995 Regulation of thyroid-stimulating hormone beta-subunit and growth hor-

- mone messenger ribonucleic acid levels in the rat: effect of vitamin A status. *Endocrinology* **136**:543–549
20. Reeves PG, Nielsen FH, Fahey GC Jr 1993 AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. *J Nutr* **123**:1939–1951.
 21. Fluttert M, Dalm S, Oitzl MS 2000 A refined method for sequential blood sampling by tail incision in rats. *Lab Anim* **34**:372–378.
 22. Catignani GL, Bieri JG 1983 Simultaneous determination of retinol and alpha-tocopherol in serum or plasma by liquid chromatography. *Clin Chem* **29**:708–712.
 23. Bieri JG, Tolliver TJ, Catignani GL 1979 Simultaneous determination of alpha-tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. *Am J Clin Nutr* **32**:2143–2149
 24. Drill VA 1943 Interrelations between thyroid function and vitamin metabolism. *Physiol Rev* **23**:355–379
 25. Strum JM 1979 Alterations within the rat thyroid gland during vitamin A deficiency. *Am J Anat* **156**:169–182
 26. Higuere P, Garcin H 1982 Peripheral metabolism of thyroid hormones in vitamin A-deficient rats. *Ann Nutr Metab* **26**:191–200.
 27. Döhler KD, Wong CC, von zur Mühlen A 1979 The rat as model for the study of drug effects on thyroid function: consideration of methodological problems. *Pharmac Ther* **5**:305–318.
 28. van Bennekum AM, Wei S, Gamble MV, Vogel S, Piantedosi R, Gottesman M, Episkopou V, Blaner WS 2001 Biochemical basis for depressed serum retinol levels in transthyretin-deficient mice. *J Biol Chem* **276**:1107–1113.
 29. Navab M, Smith JE, Goodman DS 1977 Rat plasma prealbumin. Metabolic studies on effects of vitamin A status and on tissue distribution. *J Biol Chem* **252**:5107–5114.
 30. Smith JE, DeMoor LM, Handler CE, Green EL, Ritter SJ 1998 The complex between retinol and retinol-binding protein is formed in the rough microsomes of liver following repletion of vitamin A-depleted rats. *Biochim Biophys Acta* **1380**:10–20.
 31. Higuere P, Garcin H 1979 Transport of thyroxine in the serum of vitamin A-deficient rats. *J Endocrinol* **80**:223–228.
 32. Woeber KA, Ingbar SH 1968 The contribution of thyroxine-binding prealbumin to the binding of thyroxine in human serum, as assessed by immunoabsorption. *J Clin Invest* **47**:1710–1721.
 33. Brown G, Brennan RD, Yates FE 1970 Simulation of the thyroid hormone-binding protein interactions in human plasma. *J Clin Endocrinol Metab* **30**:733–751.
 34. Wolde-Gebriel Z, Gebru H, Fisseha T, West CE 1993 Severe vitamin A deficiency in a rural village in the Hararge region of Ethiopia. *Eur J Clin Nutr* **47**:104–114.
 35. Li D, Li T, Wang F, Tian H, Samuels HH 2002 Functional evidence for retinoid X receptor (RXR) as a nonsilent partner in the thyroid hormone receptor/RXR heterodimer. *Mol Cell Biol* **22**:5782–5792
 36. Li D, Yamada T, Wang F, Vulin AI, Samuels HH 2004 Novel roles of retinoid X receptor (RXR) and RXR ligand in dynamically modulating the activity of the thyroid hormone receptor/RXR heterodimer. *J Biol Chem* **279**:7427–7437

Address reprint requests to:

Ralf Biebinger
Human Nutrition Laboratory
Institute of Food Science and Nutrition
ETH Zurich
Schmelzbergstrasse 7
8092 Zurich
Switzerland

E-mail: ralf.biebinger@ilw.agrl.ethz.ch

